Using Acalabrutinib in CLL Patients With Ibrutinib Intolerance
Jacqueline C. Barrientos, MD, MS, discusses the role of acalabrutinib, a second-generation BTK inhibitor, that is available for patients with chronic lymphocytic leukemia, but not yet approved.
Jacqueline C. Barrientos, MD, MS, associate professor in the department of medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, discusses the role of acalabrutinib (Calquence), a second-generation BTK inhibitor, that is available for patients with chronic lymphocytic leukemia (CLL), but not yet approved by the FDA.
Acalabrutinib has demonstrated activity in patients with CLL who are intolerant to ibrutinib (Imbruvica), says Barrientos. In addition, this agent appears promising in the frontline and for treatment of patients with relapsed/refractory disease.
